Jagsonpal Pharmaceuticals Limited — Updates, 26-07-2025: Press Release

Jagsonpal Pharma delivered a robust Q1FY26. Revenue surged 23% YoY to ₹75.6 Cr, with Operating EBITDA at ₹15.7 Cr (20.8% margin), up 24%. Net profit doubled to ₹10.8 Cr, showcasing strong operational execution and margin expansion. The company generated ₹15.3 Cr in free cash, bolstering its cash position to ₹160.9 Cr for future growth. Management highlighted gaining market share, reaching #7 in Gynae CVM, and confirmed plans to deepen domestic market presence. They are actively exploring strategic acquisitions to fuel further expansion.